Joseph C. Boktor

Joseph C. Boktor

Auto-generated profile, based on publicly available information

Joseph C. Boktor

Division of Biology and Biological Engineering, California Institute of Technology

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in Pediatric Research
Verified
Journal Article
Closed access
COChin Siang Ong
Chin Siang Ong
PYPooja Yesantharao
Pooja Yesantharao
CHChen Yu Huang
Chen Yu Huang
GMGunnar Mattson
Gunnar Mattson
JBJoseph Boktor
Joseph Boktor
NHNarutoshi Hibino
Narutoshi Hibino

24 January 2023 in Movement Disorders
Verified
Journal Article
Open access
JBJoseph C. Boktor
Joseph C. Boktor
GSGil Sharon
Gil Sharon
LMLeo A. Verhagen Metman
Leo A. Verhagen Metman
DHDeborah A. Hall
Deborah A. Hall
PEPhillip A Engen
Phillip A Engen
SMSarkis K. Mazmanian
Sarkis K. Mazmanian
Background: The gut microbiome is altered in several neurologic disorders, including Parkinson's disease (PD).Objectives: The aim is to profile the fecal gut metagenome in PD for alterations in microbial composition, taxon abundance, metabolic pathways, and microbial gene products, and their relationship with disease progression.Methods: Shotgun metagenomic sequencing was conducted on 244 stool donors from two independent cohorts in the United States, including individuals with PD (n = 48, n = 47, respectively), environmental household controls (HC, n = 29, n = 30), and community population controls (PC, n = 41, n = 49). Microbial features consistently altered in PD compared to HC and PC subjects were identified. Data were cross‐referenced to public metagenomic data sets from two previous studies in Germany and China to determine generalizable microbiome features.Results: We find several significantly altered taxa between PD and controls within the two cohorts sequenced in this study. Analysis across global cohorts returns consistent changes only in Intestinimonas butyriciproducens. Pathway enrichment analysis reveals disruptions in microbial carbohydrate and lipid metabolism and increased amino acid and nucleotide metabolism in PD. Global gene‐level signatures indicate an increased response to oxidative stress, decreased cellular growth and microbial motility, and disrupted intercommunity signaling.Conclusions: A metagenomic meta‐analysis of PD shows consistent and novel alterations in functional metabolic potential and microbial gene abundance across four independent studies from three continents. These data reveal that stereotypic changes in the functional potential of the gut microbiome are a consistent feature of PD, highlighting potential diagnostic and therapeutic avenues for future research. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

1 September 2019 in Translational Research
Verified
Journal Article
Closed access
SASara Abdollahi
Sara Abdollahi
JBJoseph Boktor
Joseph Boktor
NHNarutoshi Hibino
Narutoshi Hibino

10 June 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
Livia Hecke MoraisLivia Hecke Morais
Livia Hecke Morais
JBJoseph C. Boktor
Joseph C. Boktor
SMSiamak MahmoudianDehkordi
Siamak MahmoudianDehkordi
RKRima Kaddurah-Daouk
Rima Kaddurah-Daouk
SMSarkis K. Mazmanian
Sarkis K. Mazmanian
Pathological forms of the protein α-synuclein contribute to a family of disorders termed synucleinopathies, which includes Parkinson’s disease (PD). Most cases of PD are believed to arise from gene-environment interactions. Microbiome composition is altered in PD, and gut bacteria are causal to symptoms and pathology in animal models. To explore how the microbiome may impact PD-associated genetic risks, we quantitatively profiled nearly 630 metabolites from 26 biochemical classes in the gut, plasma, and brain of α-synuclein-overexpressing (ASO) mice with or without microbiota. We observe tissue-specific changes driven by genotype, microbiome, and their interaction. Many differentially expressed metabolites in ASO mice are also dysregulated in human PD patients, including amine oxides, bile acids and indoles. Notably, levels of the microbial metabolite trimethylamine N-oxide (TMAO) strongly correlate from the gut to the plasma to the brain, identifying a product of gene-environment interactions that may influence PD-like outcomes in mice. TMAO is elevated in the blood and cerebral spinal fluid of PD patients. These findings uncover broad metabolomic changes that are influenced by the intersection of host genetics and the microbiome in a mouse model of PD.

21 July 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
JBJoseph C. Boktor
Joseph C. Boktor
GSGil Sharon
Gil Sharon
LMLeo A. Verhagen Metman
Leo A. Verhagen Metman
DHDeborah A. Hall
Deborah A. Hall
PEPhillip A Engen
Phillip A Engen
SMSarkis K. Mazmanian
Sarkis K. Mazmanian
Background: The gut microbiome is altered in several neurologic disorders including Parkinson’s disease (PD). Objectives: Profile the fecal gut metagenome in PD for alterations in microbial composition, taxon abundance, metabolic pathways, and microbial gene products, and their relationship with disease progression. Methods: Shotgun metagenomic sequencing was conducted on 244 stool donors from two independent cohorts in the United States, including individuals with PD (n=48, n=47, respectively), environmental Household Controls (HC, n=29, n=30), and community Population Controls (PC, n=41, n=49). Microbial features consistently altered in PD compared to HC and PC subjects were identified. Data were cross-referenced to public metagenomic datasets from two previous studies in Germany and China to determine generalizable microbiome features. Results: The gut microbiome in PD shows significant alterations in community composition. Robust taxonomic alterations include depletion of putative “beneficial” gut commensals Faecalibacterium prausnitzii and Eubacterium and Roseburia species, and increased abundance of Akkermansia muciniphila and Bifidobacterium species. Pathway enrichment analysis and metabolic potential, constructed from microbial gene abundance, revealed disruptions in microbial carbohydrate and lipid metabolism and increased amino acid and nucleotide metabolism. These global gene-level signatures indicate an increased response to oxidative stress, decreased cellular growth and microbial motility, and disrupted inter-community signaling. Conclusions: A metagenomic meta-analysis of PD shows consistent and novel alterations in taxonomic representation, functional metabolic potential, and microbial gene abundance across four independent studies from three continents. These data reveal stereotypic changes in the gut microbiome are a consistent feature of PD, highlighting potential diagnostic and therapeutic avenues for future research.

21 September 2025 in bioRxiv
Verified
Preprint
Open access
AMAnastasiya Moiseyenko
Anastasiya Moiseyenko
GAGiacomo Antonello
Giacomo Antonello
ASAubrey M. Schonhoff
Aubrey M. Schonhoff
JBJoseph C. Boktor
Joseph C. Boktor
KLKaelyn Long
Kaelyn Long
SMSarkis K. Mazmanian
Sarkis K. Mazmanian
Gut microbiome composition is altered in Parkinson’s disease (PD), a neurodegenerative disorder characterized by motor dysfunction and frequently accompanied by gastrointestinal (GI) symptoms. Notably, microbial taxa with anti-inflammatory properties are consistently depleted in PD patients compared to controls. To explore whether specific gut bacteria may be disease-protective, we assembled a microbial consortium of 8 human-associated taxa that are reduced in individuals with PD across multiple cohorts and geographies. Treatment of α-synuclein overexpressing (Thy1-ASO) mice, an animal model of PD, with this consortium improved motor and GI deficits. A single bacterial species from this consortium, Faecalibacterium prausnitzii , was sufficient to correct gut microbiome deviations in Thy1-ASO mice, induce anti-inflammatory immune responses, and promote protective colonic gene expression profiles. Accordingly, oral treatment with F. prausnitzii robustly ameliorated motor and GI symptoms and reduced α-synuclein aggregates in the brain. These findings support the emerging hypothesis of functional contributions by the microbiome to PD and embolden development of potential probiotic therapies.